143 related articles for article (PubMed ID: 38022677)
1. Significance of NotchScore and JAG1 in predicting prognosis and immune response of low-grade glioma.
Shi B; Ge F; Cai L; Yang Y; Guo X; Wu R; Fan Z; Cao B; Wang N; Si Y; Lin X; Dong W; Sun H
Front Immunol; 2023; 14():1247288. PubMed ID: 38022677
[TBL] [Abstract][Full Text] [Related]
2. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
3. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
4. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
6. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
7. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
[TBL] [Abstract][Full Text] [Related]
8. Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.
Yang J; Shen L; Yang J; Qu Y; Gong C; Zhou F; Liu Y; Luo M; Zhao L
Transl Cancer Res; 2024 Jan; 13(1):112-136. PubMed ID: 38410234
[TBL] [Abstract][Full Text] [Related]
9. Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer.
Lee J; Lee J; Kim JH
Cell Oncol (Dordr); 2020 Oct; 43(5):821-834. PubMed ID: 32483746
[TBL] [Abstract][Full Text] [Related]
10. Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.
Zhang J; Yang Y; Dong Y; Liu C
Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34913078
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.
Ma P; Zou C; Xia S
Immunogenetics; 2022 Dec; 74(6):539-557. PubMed ID: 35895154
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of mitochondrial transcription elongation factor (TEFM) predicts poor prognosis in low grade glioma-an analysis of the Cancer Genome Atlas (TCGA) dataset.
Li S; Wang W; Zi J; Sun M; Mei W; Yang N; Zhang R; Yu M; Xiong W
Transl Cancer Res; 2020 May; 9(5):3610-3622. PubMed ID: 35117724
[TBL] [Abstract][Full Text] [Related]
13. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
14. Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients.
Zhang T; Zhang Q; He X; Lu Y; Shao A; Sun X; Shao Y
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474320
[TBL] [Abstract][Full Text] [Related]
15. Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.
Huang R; Li Z; Zhu X; Yan P; Song D; Yin H; Hu P; Lin R; Wu S; Meng T; Zhang J; Huang Z
J Cell Mol Med; 2020 Sep; 24(18):10803-10815. PubMed ID: 32757451
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma.
Lu Z; Chen Y; Chen S; Zhu X; Wang C; Wang Z; Yao Q
Oxid Med Cell Longev; 2022; 2022():1494520. PubMed ID: 36531205
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
19. SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway.
Li X; Li G; Li L; Gao B; Niu X; Wang Y; Wang Z
Brain Behav; 2024 Mar; 14(3):e3465. PubMed ID: 38468469
[TBL] [Abstract][Full Text] [Related]
20. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
